is jardiance a glp-1 Eli Lilly, Boehringer's flops heart failure trial, falling behind AZ's Farxiga is jardiance a glp-1 receptor

10.1016/j.phrs.2018.03.020 76 IzzoC.AnnunziataM.MelaraG.SciorioR.DallioM.MasaroneM.et al (2021)

To view a copy of this licence, visit About this article Cite this article Zhou, C., Segura-Covarrubias, G

Le Page A, Dupuis G, Larbi A, Witkowski JM, Fulop T

10.1016/j.bmc.2018.01.006 44 DerosaG.MaffioliP.FerrariI.MereuR.RagonesiP

Dulaglutide In 2014, the FDA approved the marketing of the long-acting GLP-1RAs dulaglutide (dulaglutide) developed by Eli Lilly and Company, with the trade name Trulicity

The peptide has never received regulatory approval in any jurisdiction and has not advanced beyond early-stage research in the clinical development pipeline